<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04837040</url>
  </required_header>
  <id_info>
    <org_study_id>CRN00808-09</org_study_id>
    <secondary_id>2020-005431-70</secondary_id>
    <nct_id>NCT04837040</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly</brief_title>
  <acronym>PATHFNDR-1</acronym>
  <official_title>A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Acromegaly Treated With Long-acting Somatostatin Receptor Ligands (PATHFNDR-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crinetics Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crinetics Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, placebo-controlled study designed to evaluate the safety and efficacy of&#xD;
      paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2&#xD;
      biased agonist) in subjects with acromegaly previously treated with somatostatin receptor&#xD;
      ligand (SRL) based treatment regimens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who maintain biochemical response in IGF-1 (≤1.0× the upper limit of normal [ULN]) at the End of the Randomized Control Phase (EOR)</measure>
    <time_frame>36 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in IGF-1 to EOR</measure>
    <time_frame>36 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with GH &lt;1.0 ng/mL at Week 34, out of those who had GH &lt;1.0 ng/mL at Screening</measure>
    <time_frame>36 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Total Acromegaly Symptoms Diary (ASD) score to EOR</measure>
    <time_frame>36 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Paltusotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paltusotine</intervention_name>
    <description>Paltusotine, tablets, once daily by mouth</description>
    <arm_group_label>Paltusotine</arm_group_label>
    <other_name>CRN00808</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, tablets, once daily by mouth</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects ≥18 years of age&#xD;
&#xD;
          2. Confirmed diagnosis of acromegaly and controlled (as measured by IGF-1 &lt;ULN) via&#xD;
             stable dose of protocol defined somatostatin receptor ligand therapy&#xD;
&#xD;
          3. Females must be non-pregnant and non-lactating, and either surgically sterile,&#xD;
             post-menopausal, or using effective method(s) of birth control&#xD;
&#xD;
          4. Willing to provide signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment naïve acromegaly subjects&#xD;
&#xD;
          2. Prior treatment with paltusotine&#xD;
&#xD;
          3. Pituitary surgery within 24 weeks prior to Screening or history of pituitary radiation&#xD;
             therapy&#xD;
&#xD;
          4. History or presence of malignancy except adequately treated basal cell and squamous&#xD;
             cell carcinomas of the skin within the past 5 years&#xD;
&#xD;
          5. Use of any investigational drug within the past 30 days or 5 half-lives, whichever is&#xD;
             longer&#xD;
&#xD;
          6. Known history of HIV, hepatitis B, or active hepatitis C&#xD;
&#xD;
          7. History of alcohol or substance abuse in the past 12 months&#xD;
&#xD;
          8. Any condition that in the opinion of the investigator would jeopardize the subject's&#xD;
             appropriate participation in this study&#xD;
&#xD;
          9. Cardiovascular conditions or medications associated with prolonged QT or those which&#xD;
             predispose subjects to heart rhythm abnormalities&#xD;
&#xD;
         10. Subjects with symptomatic cholelithiasis&#xD;
&#xD;
         11. Subjects with clinically significant abnormal findings during the Screening Period, or&#xD;
             any other medical condition(s) or laboratory findings that, in the opinion of the&#xD;
             Investigator, might jeopardize the subject's safety or ability to complete the study&#xD;
&#xD;
         12. Subjects currently taking pasireotide LAR (within 24 weeks prior to Screening) or&#xD;
             pegvisomant, dopamine agonists, or short acting somatostatin analogs (with 12 weeks&#xD;
             prior to Screening)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Crinetics Clinical Trials</last_name>
    <phone>833-827-9741</phone>
    <email>clinicaltrials@crinetics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Lundquist Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metabolic Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allegheny Endocrinology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midstate Endocrine Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spółka Lekarzy Intercor</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-605</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oddzial Kliniczny Endokrynologii</name>
      <address>
        <city>Poznań</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mazowiecki Szpital Brodnowski</name>
      <address>
        <city>Warszawa</city>
        <zip>03-242</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Endokrynologii, Diabetologii i Leczenia Izotopami</name>
      <address>
        <city>Wrocław</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://studykik.com/4016363-acromegaly?utm=ctgov</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acromegaly</keyword>
  <keyword>PATHFNDR</keyword>
  <keyword>Paltusotine</keyword>
  <keyword>CRN00808</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

